Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

Phase 2 Recruiting 15 enrolled Unity Health Toronto Toronto Metropolitan University · collab University of Ottawa · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).

Timeline

Start: 2026-06
Primary completion: 2027-01
Completion: 2027-01

Publications

Meshkat S, J Zeifman R, Stewart K, Janssen-Aguilar R, Lou W, Jetly R, Monson CM, Bhat V. Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial. PLoS One. 2025 Jan 17;20(1):e0313741. doi: 10.1371/journal.pone.0313741. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	25 mg	—

Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

Summary

Timeline

Publications

Drugs

Indications